Brexi0.5 mg

Brexi is an atypical antipsychotic (serotonin-dopamine activity modulator) indicated for:

FDA-approved (established) indications

• Schizophrenia — for the treatment of schizophrenia in adults and adolescents aged 13 years and older.
• Major depressive disorder (MDD) — adjunctive therapy — used in adults in combination with an oral antidepressant when response to antidepressant therapy alone has been inadequate. Brexi is not indicated as monotherapy for depression.
• Agitation associated with dementia due to Alzheimer's disease — for the treatment of agitation symptoms (e.g., aggression, irritability, agitated behavior) in adults with Alzheimer's dementia.

Important distinction: Brexi is not approved for the treatment of psychosis related to dementia (dementia-related psychosis); see Precautions and Warnings regarding the boxed mortality warning in elderly dementia patients.

Off-label / investigational use

Brexi has been studied off-label for other psychiatric indications (e.g., as an add-on in certain anxiety or agitation states), but such use is not FDA-approved and should only be undertaken under specialist psychiatric supervision.

Brexi is an atypical (second-generation) antipsychotic medicine, chemically and pharmacologically classified as a serotonin-dopamine activity modulator (SDAM). It was developed as a successor to aripiprazole with a modified receptor-binding profile intended to reduce activation-related side effects while retaining antipsychotic and mood-stabilizing efficacy.

Brexi is used in the management of schizophrenia, as adjunctive therapy for major depressive disorder, and for agitation associated with Alzheimer's dementia. It is administered orally as a once-daily tablet, usually starting at a low dose that is gradually increased (titrated) to the target maintenance dose to improve tolerability.

Atypical Antipsychotic (Serotonin-Dopamine Activity Modulator)

Mechanism of action

Brexpiprazole acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A receptors. It also shows antagonist activity at alpha-1B and alpha-2C adrenergic receptors, with moderate affinity for histamine H1 and serotonin 5-HT7 receptors. This combined receptor profile is believed to underlie both its antipsychotic activity and its comparatively lower propensity for akathisia/activation compared with some other partial dopamine agonists.

Pharmacokinetics

• Absorption: Well absorbed orally; peak plasma concentration reached in approximately 4 hours; food does not significantly affect absorption.
• Metabolism: Extensively metabolized in the liver, primarily by the cytochrome P450 enzymes CYP3A4 and CYP2D6.
• Elimination half-life: Approximately 91 hours (main active moiety), with steady-state plasma concentrations reached in about 10–12 days of once-daily dosing.
• Excretion: Mainly via feces, with a smaller portion excreted renally.

• Brexi tablets are taken orally, once daily, with or without food.
• Swallow the tablet whole; do not crush, chew, or split unless the product is scored for splitting and a physician/pharmacist has advised it.
• Take at approximately the same time each day to maintain consistent blood levels.
• If a dose is missed, take it as soon as remembered unless it is close to the time of the next dose — in that case skip the missed dose and resume the regular schedule. Do not double the dose.
• Do not stop Brexi abruptly without consulting a physician, as symptoms may return or worsen.

Clinically significant drug interactions

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin): increase Brexi plasma levels — dose reduction of Brexi is recommended.
• Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine, quinidine): increase Brexi plasma levels — dose reduction of Brexi is recommended.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's Wort): decrease Brexi plasma levels significantly — dose increase may be required, or an alternative agent considered; avoid concomitant use where possible.
• CNS depressants (opioids, benzodiazepines, sedating antihistamines, alcohol): additive sedation and psychomotor impairment; use with caution.
• Antihypertensive agents: Brexi may enhance the hypotensive (blood-pressure-lowering) effect, increasing the risk of orthostatic hypotension.
• Other centrally-acting dopaminergic/serotonergic agents: caution advised due to overlapping receptor effects.

Common adverse effects

Other reported reactions

• Extrapyramidal symptoms (tremor, rigidity, restlessness)
• Dizziness, orthostatic hypotension
• Constipation, dry mouth
• Metabolic changes: elevated blood sugar, abnormal lipid levels, weight gain (see Precautions and Warnings)

Serious but less common reactions (neuroleptic malignant syndrome, tardive dyskinesia, seizures, severe allergic reactions) are discussed under Precautions and Warnings — seek prompt medical attention if these occur.

Pregnancy

Data on the use of Brexi in pregnant women are limited. Neonates exposed to antipsychotic drugs during the third trimester are at risk of extrapyramidal and/or withdrawal symptoms (agitation, abnormal muscle tone, tremor, feeding difficulty, respiratory distress) following delivery. Brexi should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and only under close physician supervision. Women exposed to Brexi during pregnancy may be encouraged to enroll in a national pregnancy registry for atypical antipsychotics, where available.

Lactation

It is not well established whether Brexi passes into human breast milk in clinically significant amounts. Because of the potential for adverse effects in a breastfed infant, a decision should be made to either discontinue breastfeeding or discontinue the drug, taking into account the importance of treatment to the mother — consult a physician before use while breastfeeding.

Boxed warning

Increased mortality in elderly patients with dementia-related psychosis: Elderly patients with dementia-related psychosis treated with antipsychotic drugs, including Brexi, are at an increased risk of death compared with placebo. Brexi is not approved for the treatment of patients with dementia-related psychosis.

Other important warnings

• Cerebrovascular adverse reactions (including stroke) have occurred in elderly patients with dementia-related psychosis.
• Neuroleptic malignant syndrome (NMS): a rare but potentially fatal reaction (hyperthermia, muscle rigidity, altered mental status, autonomic instability) — discontinue immediately if suspected.
• Tardive dyskinesia: involuntary, repetitive movements that may become irreversible; risk increases with duration of treatment and cumulative dose.
• Metabolic changes: hyperglycemia/diabetes, dyslipidemia, and weight gain have been reported; monitor blood glucose, lipids, and weight periodically.
• Orthostatic hypotension and syncope, particularly during initial dose titration — use caution in patients with cardiovascular disease or dehydration.
• Leukopenia, neutropenia, and agranulocytosis have been reported; monitor complete blood counts in patients with pre-existing low white cell counts or a history of drug-induced neutropenia.
• Seizures: use cautiously in patients with a history of seizures or conditions that lower the seizure threshold.
• Impulse-control problems: compulsive gambling, eating, shopping, or sexual urges have been reported with dopaminergic-modulating drugs including Brexi; counsel patients and caregivers, and consider dose reduction or discontinuation if such behaviors occur.
• Cognitive and motor impairment: Brexi may impair judgment, thinking, or motor skills — caution when driving or operating machinery.
• Body temperature dysregulation and dysphagia (difficulty swallowing) have also been reported with antipsychotic use.

Reported signs of Brexi overdose include sedation and somnolence, with the potential for tachycardia, hypotension, and other exaggerations of known pharmacological effects. There is no specific antidote for Brexi overdose; management is supportive and symptomatic, including cardiovascular monitoring (ECG monitoring for arrhythmia), maintenance of an adequate airway, oxygenation and ventilation as needed, and close observation until recovery.

If an overdose of Brexi is suspected, seek immediate medical attention or contact a poison control center / emergency services right away. Do not attempt to induce vomiting or manage a suspected overdose at home without professional guidance.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Pediatric use: Safety and efficacy of Brexi for schizophrenia have been established in adolescents aged 13–17 years. Safety and efficacy have not been established in children under 13 years, or for MDD/agitation indications in any pediatric population.
• Elderly patients: Use with caution, particularly in patients with dementia; see the boxed warning under Precautions and Warnings regarding increased mortality risk in elderly patients with dementia-related psychosis. When used for agitation associated with Alzheimer's dementia, treatment duration should be limited and the need for continued therapy reassessed periodically.
• Hepatic impairment: Dose reduction is recommended in moderate-to-severe hepatic impairment (Child-Pugh B/C); no adjustment typically needed for mild impairment.
• Renal impairment: Dose reduction is recommended in moderate-to-severe renal impairment and end-stage renal disease; no adjustment typically needed for mild impairment.
• CYP2D6 poor metabolizers: Reduced dose is recommended (see Dosage and Administration).
• Pregnancy and lactation: See Pregnancy and Lactation section for detailed guidance.

Duration of treatment with Brexi is individualized based on indication and clinical response. In schizophrenia, Brexi is typically continued long-term for maintenance and relapse prevention, with periodic reassessment of continued need and dose. As adjunctive therapy for major depressive disorder, response should be reassessed periodically, and the ongoing need for antipsychotic augmentation reviewed. When used for agitation associated with Alzheimer's dementia, treatment should be for the shortest duration consistent with clinical need, with regular attempts to taper or discontinue and reassessment of risks versus benefits, given the increased mortality risk associated with antipsychotic use in elderly dementia patients.

Antipsychotics > Atypical (Second-Generation) Antipsychotics > Serotonin-Dopamine Activity Modulators (SDAMs)

Brexpiprazole works as a serotonin-dopamine activity modulator: it acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, and as an antagonist at serotonin 5-HT2A receptors, with additional antagonism at alpha-adrenergic receptors. This balanced modulation of dopaminergic and serotonergic neurotransmission is thought to reduce psychotic symptoms, improve mood, and help control agitation, while aiming to limit some of the motor and activation-related side effects seen with older antipsychotics.

Brexi is approved for the treatment of schizophrenia in adolescents aged 13 years and older, using a weight/response-based titration schedule similar to (though sometimes starting lower than) the adult regimen (see Dosage and Administration). Adolescents should be monitored closely for the same risks as adults, including metabolic changes, extrapyramidal symptoms, and mood/behavioral changes.

Safety and efficacy of Brexi have not been established in children under 13 years of age, nor for adjunctive treatment of major depressive disorder or agitation associated with Alzheimer's dementia in any pediatric population (the latter indication does not apply to children). Use in these settings is not recommended outside of specialist supervision.